A clinical study for evaluating the safety of excessive consumption of the honey vinegar beverage

A clinical study for evaluating the safety of excessive consumption of the honey vinegar beverage - A clinical study for evaluating the safety of excessive consumption of the honey vinegar beverage

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016586

Enrollment

Registered

2016-06-30

Start date

2015-02-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

Excessive consumption of the honey vinegar beverage for 4 weeks Excessive consumption of the control beverage without honey vinegar for 4 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Subjects aged from 20 to 65 years old 2)Subjects with high normal blood pressure(systolic BP from 130 to 139/ or diastolic BP from 85 to 89 mm Hg) or grade 1 hypertension (systolic BP from 140 to 159/ or diastolic BP from 90 to 99 mm Hg) or normotensive 3)Subjects who have a briefing of the content of the present study, fully understanding and agreeing to its objective and being able to personally sign a written informed consent

Exclusion criteria

Exclusion criteria: 1) Subjects who need an urgent anti-hypertensive treatment 2) Subjects who have a symptom of cerebrovascular diseases 3) Heart failure patients or subjects who have a history of myocardial infarction 4) Subjects who have an atrial fibrillation or a severe arrhythmia 5) Subjects who have a severe renal dysfunction (serum creatinine >=2 mg/dl) 6) Subjects who have severe hepatic, cardiovascular, respiratory disease, endocrine or metabolic disorders 7) Subjects who have a history of the hypersensitivity or an allergy for test foods in this study 8) Subjects who have a secondary hypertension 9) Subjects who regularly take any anti-hypertensive drug or FOSHU for improving hypertension 10) For female: Subjects with pregnant or breast feeding , or those who have a plan to be pregnant during the study period 11) Subject having blood sample of 200 ml or more taken (e.g., donated blood) within 1 month, or 400 ml or more within 3 months prior to the start of the present study 12) Subject who took part in another clinical study within 3 months prior to the start of the present study or who is currently taking part in another clinical study 13) Subject deemed unsuitable by the investigator

Design outcomes

Primary

Measure	Time frame
Blood chemistry, hematology, urinalysis, body weight, systolic blood pressure, diastolic blood pressure, pulse rate, medical interview	—

Countries

Japan

Contacts

Public ContactTomohiro Sugino

Soiken Inc. R&D Division

sugino@soiken.com06-6871-8888

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026